One of the best-known cancer amplicons is observed around the ERBB2 locus, at chromosome 17q12, in a subset of breast cancers which become sensitive to treatments specifically targeting the over-expressed HER2 (Human EGFR family Receptor 2) receptor. Here, ERBB2 is linked to breast carcinoma.